Denosumab in postmenopausal women with low bone mineral density.
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Receptor activator of nuclear factor-kappaB ligand (RANKL) is essential for osteoclast differentiation, activation, and survival. The fully human monoclonal antibody denosumab (formerly known as AMG 162) binds RANKL with high affinity and specificity and inhibits RANKL action. METHODS: The efficacy and safety of subcutaneously administered denosumab were evaluated over a period of 12 months in 412 postmenopausal women with low bone mineral density (T score of -1.8 to -4.0 at the lumbar spine or -1.8 to -3.5 at the proximal femur). Subjects were randomly assigned to receive denosumab either every three months (at a dose of 6, 14, or 30 mg) or every six months (at a dose of 14, 60, 100, or 210 mg), open-label oral alendronate once weekly (at a dose of 70 mg), or placebo. The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Changes in bone turnover were assessed by measurement of serum and urine telopeptides and bone-specific alkaline phosphatase. RESULTS: Denosumab treatment for 12 months resulted in an increase in bone mineral density at the lumbar spine of 3.0 to 6.7 percent (as compared with an increase of 4.6 percent with alendronate and a loss of 0.8 percent with placebo), at the total hip of 1.9 to 3.6 percent (as compared with an increase of 2.1 percent with alendronate and a loss of 0.6 percent with placebo), and at the distal third of the radius of 0.4 to 1.3 percent (as compared with decreases of 0.5 percent with alendronate and 2.0 percent with placebo). Near-maximal reductions in mean levels of serum C-telopeptide from baseline were evident three days after the administration of denosumab. The duration of the suppression of bone turnover appeared to be dose-dependent. CONCLUSIONS: In postmenopausal women with low bone mass, denosumab increased bone mineral density and decreased bone resorption. These preliminary data suggest that denosumab might be an effective treatment for osteoporosis. (ClinicalTrials.gov number, NCT00043186.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Denosumab administration in postmenopausal women with low BMD resulted in gains in BMD at the total hip, femoral neck, and distal radius at 12 and 24 months (230).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“at the total hip of 1.9 to 3.6% (vs.an increase of 2% with alendronate and a loss of 0.6% with placebo)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“Treatment with denosumab resulted in a mean increase in BMD at the lumbar spine of 3.0 to 6.7% (vs.an increase of 4.6% with alendronate and a loss of 0.8% with placebo)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“Those gains in BMD were associated with decreases in bone resorption.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“and at the distal third of the radius of 0.4 to 1.3% (vs.decreases of 0.5% with alendronate and 2.0% with placebo).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
Citations
Cites
An analysis of variance test for normality (complete samples)
SHAPIRO, S. S., & WILK, M. B. (1965) · Biometrika · doi:10.1093/biomet/52.3-4.591 · Cited by 23,480
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Bekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040305 · Cited by 771
Self-citationThe ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
Burgess, T. L., Qian, Y.-X., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., et al. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.3.527 · Cited by 689
Research works printed but not linked: 3
- Schroeder K, 2004, Cochrane Database Syst Rev, 2, CD004804
- van Elteren PH, 1960, Bull Int Stat Inst, 37, 351
- Schnitzer T, 2000, Aging (Milano), 12, 1
Cited by
Items 201–300 of 1,000
Increasing Options for the Treatment of Osteoporosis
Khosla, S. (2009) · New England Journal of Medicine · doi:10.1056/nejme0905480 · Cited by 86
Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications
Body, J. J., Bergmann, P., Boonen, S., Devogelaer, J.-P., Gielen, E., Goemaere, S., Kaufman, J., Rozenberg, S., & Reginster, J.-Y. (2012) · Osteoporosis International · doi:10.1007/s00198-011-1891-8 · Cited by 96
Diker‐Cohen, T., Rosenberg, D., Avni, T., Shepshelovich, D., Tsvetov, G., & Gafter‐Gvili, A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz322 · Cited by 84
Macías, J. G., Gay, N. G., Alonso, C. G., Barquero, L. M. D. R., Torres, M. M., Delgado‐Rodríguez, M., Pérez-Edo, L., López, J. B. D., Gimeno, E. J., & Carranza, F. H. (2008) · Revista Clínica Española · doi:10.1016/s0014-2565(08)71780-6 · Cited by 111
Key roles of the OPG–RANK–RANKL system in bone oncology
Baud’huin, M., Duplomb, L., Velasco, C. R., Fortun, Y., Heymann, D., & Padrines, M. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.2.221 · Cited by 87
Skeletal responses to romosozumab after 12 months of denosumab
McClung, M. R., Bolognese, M. A., Brown, J. P., Reginster, J., Langdahl, B. L., Shi, Y., Timoshanko, J., Libanati, C. R., Chines, A. A., & Oates, M. K. (2021) · JBMR Plus · doi:10.1002/jbm4.10512 · Cited by 83
Self-citationPhysiological Functions of Osteoblast Lineage and T Cell–Derived RANKL in Bone Homeostasis
Fumoto, T., Takeshita, S., Ito, M., & Ikeda, K. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2096 · Cited by 75
Mitsiades, C. S., Davies, F. E., Laubach, J. P., Joshua, D., Miguel, J. S., Anderson, K. C., & Richardson, P. G. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.0760 · Cited by 83
Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro
Cantley, M. D., Fairlie, D. P., Bartold, P. M., Rainsford, K. D., Le, G. T., Lucke, A. J., Holding, C. A., & Haynes, D. R. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22684 · Cited by 87
Tanaka, Y., & Ohira, T. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.03.006 · Cited by 81
Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider
Tripto‐Shkolnik, L., Fund, N., Rouach, V., Chodick, G., Shalev, V., & Goldshtein, I. (2019) · Bone · doi:10.1016/j.bone.2019.115150 · Cited by 81
Treatment needs and current options for postmenopausal osteoporosis
Gennari, L., Rotatori, S., Bianciardi, S., Nuti, R., & Merlotti, D. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1176147 · Cited by 85
Samadfam, R., Xia, Q., & Goltzman, D. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060915 · Cited by 80
Treatment of post-menopausal osteoporosis: beyond bisphosphonates
Ishtiaq, S., Fogelman, I., & Hampson, G. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0152-z · Cited by 85
Osteoporosis and osteopenia: implications for periodontal and implant therapy
Otomo‐Corgel, J. (2012) · Periodontology 2000 · doi:10.1111/j.1600-0757.2011.00435.x · Cited by 89
Yue, J., Griffith, J. F., Xiao, F., Shi, L., Wang, D., Shen, J., Wong, P. C. H., Li, E. K., Li, M., Li, T. K., et al. (2016) · Arthritis Care & Research · doi:10.1002/acr.23133 · Cited by 79
New and emerging concepts in the use of denosumab for the treatment of osteoporosis
Lewiecki, E. M. (2018) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x18805759 · Cited by 75
Self-citationInflammation-Induced Bone Loss: Can it Be Prevented?
Romas, E., & Gillespie, M. T. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.07.004 · Cited by 87
Furuya, Y., Inagaki, A., Khan, M., Mori, K., Penninger, J. M., Nakamura, M., Udagawa, N., Aoki, K., Ohya, K., Uchida, K., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.426080 · Cited by 77
Peterson, M., & Riggs, M. (2015) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.20 · Cited by 77
Self-citationLeere, J. S., Karmisholt, J., Robaczyk, M. G., Lykkeboe, S., Handberg, A., Steinkohl, E., Frøkjær, J. B., & Vestergaard, P. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30063-2 · Cited by 79
Aicher, A., Kollet, O., Heeschen, C., Liebner, S., Urbich, C., Ihling, C., Orlandi, A., Lapidot, T., Zeiher, A. M., & Dimmeler, S. (2008) · Circulation Research · doi:10.1161/circresaha.107.172718 · Cited by 73
Denosumab in Osteoporosis and Oncology
Burkiewicz, J. S., Scarpace, S. L., & Bruce, S. P. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m102 · Cited by 82
Karsdal, M. A., Henriksen, K., Arnold, M., & Christiansen, C. (2008) · BioDrugs · doi:10.2165/00063030-200822030-00001 · Cited by 85
Normocalcemic primary hyperparathyroidism
Cusano, N. E., & Cetani, F. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000556 · Cited by 75
Management of normocalcemic primary hyperparathyroidism
Cusano, N. E., Cipriani, C., & Bilezikian, J. P. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.09.009 · Cited by 75
Denosumab: A Review of its Use in the Treatment of Postmenopausal Osteoporosis
Moen, M. D., & Keam, S. J. (2010) · Drugs & Aging · doi:10.2165/11203300-000000000-00000 · Cited by 75
Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.
de Nijs, R. N. J. (2008) · PubMed · Cited by 87
Signaling Axis in Osteoclast Biology and Therapeutic Targeting in the RANKL/RANK/OPG System
Tanaka, S. (2007) · American Journal of Nephrology · doi:10.1159/000106484 · Cited by 84
Stem cells applications in bone and tooth repair and regeneration: New insights, tools, and hopes
Meguid, E. M. A., Ke, Y., Ji, J., & El-Hashash, A. H. K. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25940 · Cited by 83
Biological agents in management of osteoporosis
Tella, S. H., & Gallagher, J. C. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1735-5 · Cited by 77
Schett, G. A., Stolina, M., Dwyer, D., Zack, D. J., Uderhardt, S., Krönke, G., Kostenuik, P. J., & Feige, U. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24767 · Cited by 79
A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis
Miller, P. D. (2011) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x11424220 · Cited by 76
Self-citationSoluble RANKL Induces High Bone Turnover and Decreases Bone Volume, Density, and Strength in Mice
Lloyd, S. A. J., Yuan, Y. Y., Kostenuik, P. J., Ominsky, M. S., Lau, A. G., Morony, S., Stolina, M., Asuncion, F., & Bateman, T. A. (2008) · Calcified Tissue International · doi:10.1007/s00223-008-9133-6 · Cited by 77
Pelletier, J., Martel‐Pelletier, J., & Raynauld, J. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1932 · Cited by 79
Schett, G. A. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2166 · Cited by 83
The dynamic interplay between osteoclasts and the immune system
Nakashima, T., & Takayanagi, H. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.04.004 · Cited by 78
Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies
Byrjalsen, I., Leeming, D. J., Qvist, P., Christiansen, C., & Karsdal, M. A. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0462-5 · Cited by 74
RANKL as a target for the treatment of osteoporosis
Matsumoto, T., & Endo, I. (2020) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-020-01153-7 · Cited by 76
Solomon, D. H., Finkelstein, J. S., Shadick, N. A., LeBoff, M. S., Winalski, C. S., Stedman, M. R., Glass, R. J., Brookhart, M. A., Weinblatt, M. E., & Gravallese, E. M. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24551 · Cited by 71
Osteopenia and cancer in children and adolescents: The fragility of success
Sala, A., & Barr, R. D. (2007) · Cancer · doi:10.1002/cncr.22546 · Cited by 71
Kristensen, B., Ejlertsen, B., Mouridsen, H. T., Jensen, M., ANDERSEN, J. E., Jensen, B. B., Cold, S., Edlund, P., Ewertz, M., Kamby, C., et al. (2008) · Acta Oncologica · doi:10.1080/02841860801964988 · Cited by 70
Mouse Models in Bone Fracture Healing Research
Haffner‐Luntzer, M., Kovtun, A., Rapp, A. E., & Ignatius, A. A. (2016) · Current Molecular Biology Reports · doi:10.1007/s40610-016-0037-3 · Cited by 77
RANKL blockade for erosive hand osteoarthritis: a randomized placebo-controlled phase 2a trial
Wittoek, R., Verbruggen, G., Vanhaverbeke, T., Colman, R., & Elewaut, D. S. (2024) · Nature Medicine · doi:10.1038/s41591-024-02822-0 · Cited by 69
Dietary Dried Plum Increases Bone Mass in Adult and Aged Male Mice
Halloran, B. P., Wronski, T. J., VonHerzen, D. C., Chu, V., Xia, X., Pingel, J. E., Williams, A. A., & Smith, B. J. (2010) · Journal of Nutrition · doi:10.3945/jn.110.124198 · Cited by 76
Han, X., Lin, X., Yu, X., Lin, J., Kawai, T., LaRosa, K. B., & Taubman, M. A. (2013) · Infection and Immunity · doi:10.1128/iai.00043-13 · Cited by 69
New Automated Multiplex Assay for Bone Turnover Markers in Osteoporosis
Claudon, A., Vergnaud, P., Valverde, C., Mayr, A., Klause, U., & Garnero, P. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105866 · Cited by 69
Dempster, D. W., Zhou, H., Recker, R. R., Brown, J. P., Recknor, C. P., Lewiecki, E. M., Miller, P. D., Rao, S. D., Kendler, D. L., Lindsay, R., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4181 · Cited by 71
Self-citationAnderson, P. M., Kopp, L. M., Anderson, N. R., Cornelius, K., Herzog, C. E., Hughes, D. P. M., & Huh, W. W. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.11.1703 · Cited by 68
Bouxsein, M., & Delmas, P. D. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080301 · Cited by 73
Stem Cells and Osteoporosis Therapy
Teitelbaum, S. L. (2010) · Cell stem cell · doi:10.1016/j.stem.2010.10.004 · Cited by 67
Tauchmanovà, L., Colao, A. A. L., Lombardi, G., Rotoli, B., & Selleri, C. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2870 · Cited by 69
Actualización 2011 del consenso Sociedad Española de Reumatología de osteoporosis
Pérez-Edo, L., Ruiz, A. A., Vilaseca, D. R., García-Vadillo, A., Gay, N. G., Peris, P., Eslava, A. T., Audera, C. B., Aresté, J. F., Rodríguez, L. M. A., et al. (2011) · Reumatología Clínica · doi:10.1016/j.reuma.2011.05.013 · Cited by 90
A review of denosumab for the treatment of osteoporosis
Miyazaki, T., Tokimura, F., & Tanaka, S. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s46192 · Cited by 68
Musette, P., Brandi, M. L., Cacoub, P., Kaufman, J., Rizzoli, R., & Reginster, J. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1097-5 · Cited by 66
Melatonin, bone regulation and the ubiquitin-proteasome connection: A review
Vriend, J. P., & Reiter, R. J. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.12.031 · Cited by 69
HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture
Ofotokun, I., & Weitzmann, M. N. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32833f48d6 · Cited by 70
Saylor, P. J., Keating, N. L., & Smith, M. R. (2009) · Journal of General Internal Medicine · doi:10.1007/s11606-009-0968-y · Cited by 68
Genant, H. K., Libanati, C. R., Engelke, K., Zanchetta, J., Høiseth, A. D., Yuen, C. K., Stonkus, S., Bolognese, M. A., Franek, E., Fuerst, T. P., et al. (2013) · Bone · doi:10.1016/j.bone.2013.07.011 · Cited by 65
Self-citationDenosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis
Sharp, J. T., Tsuji, W. H., Ory, P. A., Harper-Barek, C., Wang, H., & Newmark, R. (2010) · Arthritis Care & Research · doi:10.1002/acr.20172 · Cited by 67
Alternative therapies for the prevention and treatment of osteoporosis
Banu, J., Varela, E., & Fernandes, G. (2012) · Nutrition Reviews · doi:10.1111/j.1753-4887.2011.00451.x · Cited by 74
Effect of denosumab on fasting glucose in women with diabetes or prediabetes from the FREEDOM trial
Napoli, N., Pannacciulli, N., Vittinghoff, E., Crittenden, D., Yun, J., Wang, A., Wagman, R., & Schwartz, A. V. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2991 · Cited by 63
Bolognese, M. A., Teglbjærg, C. S., Zanchetta, J., Lippuner, K., McClung, M. R., Brandi, M. L., Høiseth, A. D., Lakatos, P. L., Moffett, A. H., Lorenc, R. S., et al. (2012) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2012.02.006 · Cited by 64
Self-citationDevelopment and Function of Murine B Cells Lacking RANK
Perlot, T., & Penninger, J. M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102063 · Cited by 70
The Immune Microenvironment of Myeloma
Noonan, K. A., & Borrello, I. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0086-3 · Cited by 68
Beaudoin, C., Jean, S., Bessette, L., Ste‐Marie, L., Moore, L., & Brown, J. P. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3607-6 · Cited by 63
Sims, N. A., & Ng, K. W. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0196-1 · Cited by 70
Pharmacological management of osteogenesis
Nardone, V., D’Asta, F., & Brandi, M. L. (2014) · Clinics · doi:10.6061/clinics/2014(06)12 · Cited by 67
Denosumab for Prevention of Fractures in Postmenopausal Women With Osteoporosis
Cummings, S. R., Martín, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P. D., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000363236.41902.96 · Cited by 63
Self-citationLin, T., Wang, C., Cai, X.-Z., Zhao, X., Shi, M.-M., Ying, Z., Yuan, F., Guo, C., & Yan, S.-G. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02806.x · Cited by 62
Tat, S. K., Pelletier, J., Lajeunesse, D., Fahmi, H., Duval, N., & Martel‐Pelletier, J. (2008) · Bone · doi:10.1016/j.bone.2008.04.006 · Cited by 65
Osteocytes and Skeletal Pathophysiology
Delgado‐Calle, J., & Bellido, T. (2015) · Current Molecular Biology Reports · doi:10.1007/s40610-015-0026-y · Cited by 68
Osteoporosis: Management and Treatment Strategies for Orthopaedic Surgeons
Gehrig, L. M. B., Lane, J., & O’Connor, M. I. (2008) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-200806000-00028 · Cited by 73
Titanji, K. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01851 · Cited by 64
Treatment and trials in non-metastatic castration-resistant prostate cancer
Lokeshwar, S. D., Klaassen, Z. W. A., & Saad, F. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00470-4 · Cited by 65
van der Burgh, A. C., de Keyser, C. E., Zillikens, M. C., & Stricker, B. H. C. (2021) · Drugs · doi:10.1007/s40265-021-01625-8 · Cited by 64
Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
Wu, J., Zhang, Q., Yan, G., & Jin, X. (2018) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-018-0865-3 · Cited by 60
RANKL/RANK – From bone physiology to breast cancer
Sigl, V., & Penninger, J. M. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.01.002 · Cited by 63
Bone health and prostate cancer
Saylor, P. J., & Smith, M. R. (2009) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2009.50 · Cited by 62
Treatment of osteoporosis with denosumab
Lewiecki, E. M. (2010) · Maturitas · doi:10.1016/j.maturitas.2010.02.008 · Cited by 62
Self-citationRoles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease
Bernardi, S., Bossi, F., Toffoli, B., & Fabris, B. (2016) · BioMed Research International · doi:10.1155/2016/1752854 · Cited by 62
Mundy, G. R., Oyajobi, B. O., Gutierrez, G. E., Sterling, J. A. R., Padalecki, S. S., Elefteriou, F., & Zhao, M. (2008) · Elsevier eBooks · doi:10.1016/b978-012370544-0.50020-3 · Cited by 61
Dimai, H. P., & Fahrleitner‐Pammer, A. (2022) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2022.101780 · Cited by 63
Osteoclastic bone resorption induced by innate immune responses: Bone resorption and TLR signals
Koide, M., Kinugawa, S., Takahashi, N., & Udagawa, N. (2010) · Periodontology 2000 · doi:10.1111/j.1600-0757.2010.00355.x · Cited by 63
Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis
Jules, J., Ashley, J. W., & Feng, X. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.511179 · Cited by 63
RANK ligand inhibition with denosumab for the management of osteoporosis
Lewiecki, E. M. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.10.1041 · Cited by 63
Self-citationThe Emerging Role of Osteocytes in Cancer in Bone
Atkinson, E. G., & Delgado‐Calle, J. (2019) · JBMR Plus · doi:10.1002/jbm4.10186 · Cited by 64
Rodríguez, E. G., Aubry‐Rozier, B., Stoll, D., Zaman, K., & Lamy, O. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05458-8 · Cited by 58
Peterson, M., & Riggs, M. (2012) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2012.15 · Cited by 55
Napimoga, M. H., Trindade‐da‐Silva, C. A., Carregaro, V., Farnesi-de-Assunção, T. S., Duarte, P. M., de Melo, N. F. S., & Fraceto, L. F. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200730 · Cited by 59
Novel factors modulating human β‐cell proliferation
Shirakawa, J., & Kulkarni, R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12731 · Cited by 65
Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer
Kiechl, S. J., Schramek, D., Widschwendter, M., Fourkala, E.-O., Zaikin, A. A., Jones, A., Jaeger, B. A., Rack, B. K., Janni, W. J., Scholz, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14013 · Cited by 61
Zanocco, K. A., & Yeh, M. W. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.09.012 · Cited by 63
New treatment targets in osteoporosis
Roux, S. (2010) · Joint Bone Spine · doi:10.1016/j.jbspin.2010.02.004 · Cited by 57
Interference with immune‐cell‐mediated bone resorption in periodontal disease
Han, X., Kawai, T., & Taubman, M. A. (2007) · Periodontology 2000 · doi:10.1111/j.1600-0757.2007.00215.x · Cited by 68
Fu, Q., Bustamante-Gomez, N. C., Reyes-Pardo, H., Gubrij, I. B., Escalona‐Vargas, D., Thostenson, J. D., Palmieri, M., Goellner, J. J., Nookaew, I., Barnes, C. L., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.167790 · Cited by 62
Komm, B. S., Morgenstern, D., Yamamoto, L. A., & Jenkins, S. N. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1099432 · Cited by 62
The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis
Szulc, P. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.01.022 · Cited by 62
Nakamura, T., Matsumoto, T., Sugimoto, T., & Shiraki, M. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1786-8 · Cited by 57
High-Dose Diosgenin Reduces Bone Loss in Ovariectomized Rats via Attenuation of the RANKL/OPG Ratio
Zhang, Z., Song, C., Fu, X., Liu, M., Li, Y., Pan, J., Liu, H., Wang, S., Xiang, L., Xiao, G., et al. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150917130 · Cited by 53
Metadata
- Authors
- McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., Lain, D., Kivitz, A. J., Holloway, D. L., Zhang, C., Peterson, M. C., & Bekker, P. J.
- Affiliations
- Providence Portland Medical Center (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Radiant Research (United States) (US)
- National Institutes of Health (US)
- Lake OB/GYN Associates of Mid-Florida (US)
- Indiana University School of Medicine (US)
- Colorado Center for Bone Research (US)
- University of Washington Medical Center (US)
- Altoona Center for Clinical Research (US)
- Amgen (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-02-23
- Volume
- 354
- Issue
- 8
- Pages
- 821-831
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2482202957
- Cited by
- 1,228
- References
- 17
- Citations by year
- 2026: 28 · 2025: 32 · 2024: 32 · 2023: 26 · 2022: 38 · 2021: 38 · 2020: 56 · 2019: 39 · 2018: 50 · 2017: 46 · 2016: 46 · 2015: 70 · 2014: 39 · 2013: 65 · 2012: 77
- FWCI
- 118.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- denosumab, RANKL inhibition, osteoporosis, postmenopausal women, osteopenia, bone mineral density, alendronate, bone turnover markers, C-terminal telopeptide, bone resorption, dose dependence, osteoclasts, monoclonal antibodies, lumbar spine, total hip, distal radius, treatment efficacy and safety, osteoporosis prevention
- MeSH terms
- Denosumab, Antibodies, Monoclonal, Bone Resorption, Carrier Proteins, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Membrane Glycoproteins, Middle Aged, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Bone Remodeling, Alendronate, Bone Density Conservation Agents, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.